A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Kappaproct as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients.
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Cobitolimod (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms COLLECT
- Sponsors InDex Pharmaceuticals
- 19 Oct 2016 Results of post-hoc analysis presented at the 24th United European Gastroenterology Week.
- 19 Oct 2016 Post hoc analysis results presented at the 24th United European Gastroenterology Week
- 18 Oct 2016 According to an InDex Pharmaceuticals media release, result from the COLLECT study was presented at the United European Gastroenterology Week (UEGW).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History